To evaluate the safety of uninterrupted rivaroxaban , a novel oral anticoagulant that directly inhibits factor Xa , and a vitamin K antagonist ( VKA ) in eligible adult patients with nonvalvular AF ( NVAF ) who are scheduled for a catheter ablation .